Radiation drug for people with head and neck cancer on immunotherapy
Part of Cancer clinical trials.
This study tests a radioactive drug called Y-NM600 that may help treat head and neck cancer that has spread. It is given to people who are already receiving an immunotherapy drug (like Keytruda or Opdivo) and whose cancer is stable or slightly growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck cancer (squamous cell carcinoma) that has spread to other parts of the body.
- You are currently taking one of these immunotherapy drugs: Keytruda, Opdivo, Tecentriq, Bavencio, Imfinzi, Libtayo, or Jemperli (alone or with other immunotherapy).
- Your cancer is stable or shows signs of growing but your doctor wants to continue your immunotherapy.
- You have at least one tumor that can be seen on a scan.
- You are generally able to take care of yourself (ECOG score 0-2) and expected to live at least 6 months.
- You have adequate kidney, liver, and blood cell counts (your doctor will check).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if adding an investigational drug called JNJ-90301900 to standard chemotherapy and radiation therapy works better for people with certain advanced head and neck cancers (like mouth, throat, and voice box) that have not spread to other parts of the body.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This trial tests a new cancer medication for people with head and neck cancer that has come back or spread to other parts of the body. The study aims to see if this drug can help slow or shrink the cancer and improve survival.
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
This study tests whether adding immunotherapy drugs (nimotuzumab and possibly benmelstobart) to radiation therapy after head and neck cancer surgery improves outcomes. You may qualify if you've recently had surgery for squamous cell carcinoma (a common type of head and neck cancer) and have certain risk factors that suggest your cancer could return.
This trial compares radiation therapy alone versus radiation therapy plus a targeted drug called nimotuzumab for people with advanced head and neck cancer who cannot take cisplatin chemotherapy. The goal is to see if adding nimotuzumab improves outcomes.
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.